Disulfiram (DSF), an established alcohol-aversion drug, is a candidate for repurposing in cancer treatment. DSF's antitumor activity is supported by preclinical studies, case reports, and small clinical trials; however, ongoing clinical trials of advanced-stage cancer patients encounter variable results. Here, we show that one reason for the inconsistent clinical effects of DSF may reflect interference by other drugs. Using a high-throughput screening and automated microscopy, we identify cannabidiol, an abundant component of the marijuana plant used by cancer patients to mitigate side effects of chemotherapy, as a likely cause of resistance to DSF. Mechanistically, in cancer cells, cannabidiol triggers the expression of metallothioneins providing protective effects by binding heavy metal-based substances including the bis-diethyldithiocarbamate-copper complex (CuET). CuET is the documented anticancer metabolite of DSF, and we show here that the CuET's anticancer toxicity is effectively neutralized by metallothioneins. Overall, this work highlights an example of undesirable interference between cancer therapy and the concomitant usage of marijuana products. In contrast, we report that insufficiency of metallothioneins sensitizes cancer cells toward CuET, suggesting a potential predictive biomarker for DSF repurposing in oncology.

Danish Cancer Society Research Center Copenhagen Denmark

Division of Genome Biology Department of Medical Biochemistry and Biophysics Science for Life Laboratory Karolinska Institute Stockholm Sweden

Faculty of Medicine and Dentistry Institute of Molecular and Translational Medicine Palacky University Olomouc Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc22019028

003      

CZ-PrNML

005      

20220804135259.0

007      

ta

008      

220720s2022 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1002/1878-0261.13114 $2 doi

035    __

$a (PubMed)34632694

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Buchtova, Tereza $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/0000000152331504

245    10

$a Cannabidiol-induced activation of the metallothionein pathway impedes anticancer effects of disulfiram and its metabolite CuET / $c T. Buchtova, Z. Skrott, K. Chroma, J. Rehulka, P. Dzubak, M. Hajduch, D. Lukac, S. Arampatzis, J. Bartek, M. Mistrik

520    9_

$a Disulfiram (DSF), an established alcohol-aversion drug, is a candidate for repurposing in cancer treatment. DSF's antitumor activity is supported by preclinical studies, case reports, and small clinical trials; however, ongoing clinical trials of advanced-stage cancer patients encounter variable results. Here, we show that one reason for the inconsistent clinical effects of DSF may reflect interference by other drugs. Using a high-throughput screening and automated microscopy, we identify cannabidiol, an abundant component of the marijuana plant used by cancer patients to mitigate side effects of chemotherapy, as a likely cause of resistance to DSF. Mechanistically, in cancer cells, cannabidiol triggers the expression of metallothioneins providing protective effects by binding heavy metal-based substances including the bis-diethyldithiocarbamate-copper complex (CuET). CuET is the documented anticancer metabolite of DSF, and we show here that the CuET's anticancer toxicity is effectively neutralized by metallothioneins. Overall, this work highlights an example of undesirable interference between cancer therapy and the concomitant usage of marijuana products. In contrast, we report that insufficiency of metallothioneins sensitizes cancer cells toward CuET, suggesting a potential predictive biomarker for DSF repurposing in oncology.

650    12

$a kanabidiol $x farmakologie $x terapeutické užití $7 D002185

650    _2

$a nádorové buněčné linie $7 D045744

650    _2

$a měď $x chemie $x farmakologie $7 D003300

650    12

$a disulfiram $x chemie $x farmakologie $x terapeutické užití $7 D004221

650    _2

$a lidé $7 D006801

650    _2

$a metalothionein $7 D008668

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Skrott, Zdenek $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic

700    1_

$a Chroma, Katarina $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic

700    1_

$a Rehulka, Jiri $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic

700    1_

$a Dzubak, Petr $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic

700    1_

$a Hajduch, Marian $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic

700    1_

$a Lukac, David $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic

700    1_

$a Arampatzis, Stefanos $u Danish Cancer Society Research Center, Copenhagen, Denmark

700    1_

$a Bartek, Jiri $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic $u Danish Cancer Society Research Center, Copenhagen, Denmark $u Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden $1 https://orcid.org/0000000320137525 $7 xx0046271

700    1_

$a Mistrik, Martin $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/0000000223210348

773    0_

$w MED00167281 $t Molecular oncology $x 1878-0261 $g Roč. 16, č. 7 (2022), s. 1541-1554

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34632694 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220720 $b ABA008

991    __

$a 20220804135253 $b ABA008

999    __

$a ok $b bmc $g 1822577 $s 1170271

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2022 $b 16 $c 7 $d 1541-1554 $e 20211026 $i 1878-0261 $m Molecular oncology $n Mol Oncol $x MED00167281

LZP    __

$a Pubmed-20220720